Vas Narasimhan joins the pow­er cir­cle at Davos; Ar­mo Bio, resTOR­bio rais­es $128M and $85M in IPO

→ With just a few more days be­fore he of­fi­cial­ly be­comes No­var­tis’ new CEO, Vas Narasimhan is join­ing the world’s pow­er cir­cle. Case in point: Narasimhan joined a group of big-time Eu­ro­pean CEOs who sat down with Pres­i­dent Don­ald Trump for din­ner at Davos.

→ Two IPOs pitched at a year-end blitz have ma­te­ri­al­ized. Fo­cus­ing on el­der­ly res­pi­ra­to­ry tract in­fec­tions, resTOR­bio has raised $85 mil­lion by of­fer­ing 5.7 mil­lion shares at $15. The Cam­bridge, MA biotech plans to list as $TORC, a trib­ute to the mTORC1 in­hibitors its founders be­lieve have po­ten­tial to treat a va­ri­ety of ag­ing-re­lat­ed ail­ments. Then there’s I/O play­er Ar­mo Bio­sciences, which went above its orig­i­nal $86 mil­lion for 6.7 mil­lion shares plan and bagged $128 mil­lion in­stead with an of­fer­ing of 7.5 mil­lion shares at $17. It will go on Nas­daq as $AR­MO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.